Pharma BD Deal Intelligence

Pfizer Inc. / Array BioPharma Inc.

2019 · Acquisition/Merger · $11.4B · Complete

Pfizer's $11.4B all-cash acquisition of Array BioPharma delivered BRAFTOVI and MEKTOVI, but the franchise limped for years before the payoff materialized: full FDA approval in first-line BRAF V600E-mutant metastatic colorectal cancer (Feb 2026) doubled median overall survival to 30.3 months in the BREAKWATER trial, driving combined franchise sales back to double-digit growth (+16-17% YoY in Q3/Q4 2025)—though the value-realization gap against the original purchase price still hasn't closed.

CALLED IT — OFF BY 11
Full analysis, sources & comparables →

The coverage arc

Jun 17, 2019 Array BioPharma SEC Filing - Deal Announcement Neutral

The acquisition of Array BioPharma.

Jun 19, 2019 Drug Development & Delivery (GlobalData) Bullish

GlobalData's Tajekesa Chapman: with Pfizer's proven expertise in drug development and commercialization, this deal would significantly strengthen Pfizer's…

Aug 02, 2019 Nature Biotechnology Bullish

Pfizer was lured by Array's cancer know-how, paying $11.4B for the BRAF/MEK combination that showed 48% reduction in death risk in BRAF-mutant colorectal…

Source summaries from our enrichment pipeline; follow links for originals.

All 8 sources with sentiment breakdown →

Pfizer acquired Array BioPharma in 2019 for approximately $11.4 billion ($48 per share in cash), gaining BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), BRAF/MEK inhibitors approved in BRAF-mutant melanoma, plus a pivotal-stage program in BRAF V600E-mutant metastatic colorectal cancer (BEACON trial). The colorectal opportunity advanced materially: on February 24, 2026 the FDA granted full approval to BRAFTOVI in combination with cetuximab and fluorouracil-based chemotherapy (mFOLFOX6/FOLFIRI) for first-line BRAF V600E-mutant metastatic colorectal cancer, converting the December 2024 accelerated approval. The decision rested on the Phase 3 BREAKWATER trial, in which the regimen doubled median overall survival to 30.3 months versus 15.1 months (51% reduction in risk of death) and improved median progression-free survival to 12.8 versus 7.1 months. It is the only approved targeted regimen for first-line BRAF V600E-mutant mCRC. Reflecting the new label, the franchise has returned to growth: combined Braftovi/Mektovi sales were $202M in Q3 2025 (+17% YoY) and $197M in Q4 2025 (+16% YoY), after combined 2024 sales of roughly $600M. The deal's value-realization gap against the $11.4B purchase price persists, but the first-line CRC approval reopens the largest near-term growth lever in the franchise.

Key facts

Disease & market context

BRAF-Mutant Melanoma

50K US cases/yr · $4.0B Global BRAF/MEK Inhibitor Market (melanoma, 2024)

Disease Overview

Melanoma of the skin is an aggressive malignancy arising from melanocytes, with NCI SEER estimating roughly 100,000 new U.S. cases and 8,000 deaths annually. Approximately 40-50% of cutaneous melanomas harbor activating BRAF mutations, most commonly BRAF V600E (with V600K a smaller fraction), which drive constitutive MAPK pathway signaling and tumor proliferation. BRAF-mutant melanomas tend to occur in younger patients and in areas of intermittent (rather than chronic) sun exposure. Clinical evaluation of a suspicious pigmented lesion follows ABCDE criteria (asymmetry, border, color, diameter, evolution), with definitive diagnosis by excisional biopsy and histopathology including Breslow thickness, mitotic rate, and ulceration, plus molecular testing for BRAF and related drivers. Staging per AJCC TNM incorporates tumor thickness, ulceration, and sentinel lymph node status. Management depends on stage: wide local excision for localized disease, sentinel lymph node biopsy per guideline criteria, and for stage III-IV or high-risk resected disease, adjuvant or definitive systemic therapy with immune checkpoint inhibitors (anti-PD-1 monotherapy, or PD-1 plus CTLA-4 or LAG-3 combinations) and, in BRAF V600-mutant disease, targeted BRAF/MEK inhibitor combinations. Brain metastases are common and require integrated systemic and local (radiosurgery, resection) approaches. Despite advances, metastatic melanoma remains a serious disease and long-term outcomes vary by stage and biomarker profile.

Competitive Landscape

Three approved BRAF/MEK combinations: Tafinlar+Mekinist (Novartis, first to market), Zelboraf+Cotellic (Roche), BRAFTOVI+MEKTOVI (Pfizer). BRAFTOVI's differentiation was driven by the BRAF-mutant CRC approval (BEACON trial), which expanded the franchise beyond melanoma. Immunotherapy (pembrolizumab, nivolumab) is often preferred first-line.

BRAF-Mutant Colorectal Cancer

15K US cases/yr · $1.0B BRAF+ CRC Treatment Market (2024)

Disease Overview

BRAF V600E mutations occur in approximately 8-10% of metastatic colorectal cancer patients and confer a poor prognosis with shortened overall survival compared to BRAF wild-type disease. BRAF-mutant mCRC is typically right-sided, more common in older women, and frequently associated with microsatellite instability. Molecular profiling for BRAF status is now standard at diagnosis of metastatic disease to guide targeted therapy selection.

Treatment Impact

Before BEACON, BRAF-mutant CRC had median OS of ~5 months in 2L+. BRAFTOVI + cetuximab improved median OS to 9.3 months. The triplet (with binimetinib) showed similar efficacy, so the doublet became preferred. BRAF testing is now standard in CRC molecular profiling. Growing BRAFTOVI CRC use is the primary commercial driver.

Deal timeline

Related deals — scored

DealYearValueOutcome
Pfizer Inc. / Array BioPharma Inc. (this deal)2019$11.4B72
Pfizer Inc. / BioNTech SE2020$748M100
Pfizer Inc. / FoldRx Pharmaceuticals201099
Pfizer Inc. / Medivation Inc.2016$14.0B86
Pfizer Inc. / Wyeth2009$68.0B86
Pfizer Inc. / Warner-Lambert Company2000$90.0B83
Pfizer Inc. / Arvinas, Inc.2021$2.4B77

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →